Therapeutic strategy in unresectable metastatic colorectal cancer: An updated review

Therapeutic Advances in Medical Oncology

Volumn 7, Issue 3, 2015, Pages 153-169

  Chibaudel, Benoist ^a   Tournigand, Christophe ^b   Bonnetain, Franck ^c   Richa, Hubert ^a   Benetkiewicz, Magdalena ^d   André, Thierry ^e   de Gramont, Aimery ^f  

^a Hopital Franco britannique   (France)

^b DHU ATVB   (France)

^c Hôpital de Besançon   (France)

^d Fondation ARCAD   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f GERCOR   (France)

Author keywords

chemotherapy; colorectal cancer; maintenance; molecular targeted agents; strategy; treatment

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; RAS PROTEIN; REGORAFENIB; UFT;

ANTIANGIOGENIC THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER THERAPY; DISEASE DURATION; HUMAN; MAINTENANCE CHEMOTHERAPY; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; VIRUS ONCOGENE;

EID: 84928738467     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834015572343     Document Type: Review

References (65)

1. Adams R. Meade A. Seymour M. Wilson R. Madi A. Fisher D. et al. (2011) Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 12: 642–653.
2. Adams R. Aloia T. Loyer E. Pawlik T. Taouli B. Vauthey J. (2013) Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford) 15: 91–103.
3. Alfonso G. Benavides M. Sánchez Ruiz A. Guillen-Ponce C. Safont S. Alcaide J. et al. (2014) Phase II Study of first-line mFOLFOX plus cetuximab (C) for 8 cycles followed by mFOLFOX plus C or single agent (s/a) C as maintenance therapy in patients (p) with metastatic colorectal cancer (mCRC): the MACRO-2 trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]). ESMO 2014, Abstract 4990. Ann Oncol 25 (Suppl. 4): iv167–iv209.
4. Arnold D. Graeven U. Lerchenmuller C.A. Killing B. Depenbusch R. Steffens C-C. et al. (2014) Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207). ASCO 2010. J Clin Oncol 28
5. Bennouna J. Sastre J. Arnold D. Osterlund P. Greil R. van Cutsem E. et al. (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14: 29–37.
6. Chibaudel B. (2014) OPTIMOX-aflibercept as first-line therapy in patients with unresectable metastatic colorectal cancer (VELVET). http://clinicaltrials.gov/ct2/show/NCT01802684 (accessed 16 October 2014).
7. Chibaudel B. Maindrault-Goebel F. Lledo G. Mineur L. Andre T. Bennamoun M. et al. (2009) Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX 2 Study. J Clin Oncol 27: 5727–5733.
8. Chibaudel B. Tournigand C. Bonnetain F. Hug de Larauze M. de Gramont A. Laurent-Puig P. et al. (2014 a) STRATEGIC1-multi-line therapy trial in unresectable wild-type RAS metastatic colorectal cancer: A GERCOR randomized open-label phase III study. ASCO 2014, Abstract TPS3648.
9. Chibaudel B. Tournigand C. Bonnetain F. Maindrault-Goebel F. Lledo G. Andre T. et al. (2013) Platinum-sensitivity in metastatic colorectal cancer: towards a definition. Eur J Cancer 49: 3813–3820.
10. Chibaudel B. Tournigand C. Samson B. Scheithauer W. Mesange P. Lledo G. et al. (2014 b) Bevacizumab-erlotinib as maintenance therapy in metastatic colorectal cancer. Final results of the GERCOR DREAM study. ESMO 2014, Abstract 497O. Ann Oncol 25 (Suppl. 4):iv167–iv209.
11. Cunningham D. (2014) Evaluation of MGN 1703 Maintenance treatment in patients with mCRC with tumor reduction during induction treatment (IMPALA). http://clinicaltrials.gov/ct2/show/NCT02077868 (accessed 16 October 2014).
12. Cunningham D. Humblet Y. Siena S. Khayat D. Bleiberg H. Santoro A. et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med 351: 337–345.
13. Cunningham D. Lang I. Marcuello E. Lorusso V. Ocvirk J. Shin D. et al. (2013) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): An open-label, randomised phase 3 trial. Lancet Oncol 14: 1077–1085.
14. de Gramont A. Buyse M. Abrahantes J. Burzykowski T. Quinaux E. Cervantes A. et al (2007) Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 25: 3224–3229.
15. Diaz-Rubio E. Gomez-Espana A. Massuti B. Sastre J. Abad A. Valladares M. et al. (2012) First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 17: 15–25.
16. Douillard J. Oliner K. Siena S. Tabernero J. Burkes R. Barugel M. et al. (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369: 1023–1034.
17. Douillard J. Siena S. Cassidy J. Tabernero J. Burkes R. Barugel M. et al. (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX 4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697–4705.
18. Douillard J. Siena S. Cassidy J. Tabernero J. Burkes R. Barugel M. et al. (2014 a) Final Results from PRIME: randomized phase III study of panitumumab with FOLFOX 4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 25: 1346–1355.
19. Douillard J. Zemelka T. Fountzilas G. Barone C. Schlichting M. Heighway J. et al. (2014 b) FOLFOX 4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: the randomized phase II future study. Clin Colorectal Cancer 13: 14–26 e11.
20. Giantonio B. Catalano P. Meropol N. O'Dwyer P. Mitchell E. Alberts S. et al. (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539–1544.
21. Globocan (2012) International Agency on Cancer Research. Cancer Incidence and Mortality Worldwide in 2012. Available at: http://globocan.iarc.fr/pages/fact_sheets_cancer.aspx (accessed 16 October 2014).
22. Grávalos C. Carrato A. (2014) Axitinib as maintenance treatment in patients with metastatic CRC (TTD-11-01). http://clinicaltrials.gov/ct2/show/NCT01483638 (accessed 16 October 2014).
23. Grothey A. van Cutsem E. Sobrero A. Siena S. Falcone A. Ychou M. et al. (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 Trial. Lancet 381: 303–312.
24. Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente (GISCAD) (2014) Trial comparing two sequences of therapy in colorectal metastatic patients (COMETS). http://clinicaltrials.gov/ct2/show/NCT01030042 (accessed 16 October 2014).
25. Hecht J. Cohn A. Dakhil S. Saleh M. Piperdi B. Cline-Burkhardt V. et al. (2013) SPIRITT (Study 20060141): A Randomized phase II study of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with wild-type KRAS metastatic colorectal cancer. ASCO GI 2013. J Clin Oncol 31(Suppl. 4): abstract 454.
26. Hecht J. Mitchell E. Chidiac T. Scroggin C. Hagenstad C. Spigel D. et al. (2009) A randomized phase IIIb trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27: 672–680.
27. Hegewisch-Becker S. Graeven U. Lerchenmüller C. Killing B. Depenbusch R. Steffens C. et al. (2014) Maintenance strategy with fluoropyrimidine (FP) plus bevacizumab (Bev), Bev alone or no treatment, following a 24-week-first-line induction with FP, oxaliplatin (Ox) and Bev for patients with metastatic colorectal cancer: Mature data and subgroup analysis. ESMO 2014, abstract 498O.
28. Heinemann V. von Weikersthal L. Decker T. Kiani A. Vehling-Kaiser U. Al-Batran S. et al. (2014) Lancet Oncol FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15: 1065–1075.
29. Hurwitz H. Fehrenbacher L. Novotny W. Cartwright T. Hainsworth J. Heim W. et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342.
30. Hurwitz H. Kabbinavar F. (2005) Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. Oncology 69(Suppl. 3): 17–24.
31. Johnsson A. Hagman H. Frodin J. Berglund A. Keldsen N. Fernebro E. et al. (2013) A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: The NORDIC ACT trial. Ann Oncol 24: 2335–2341.
32. Jonker D. O'Callaghan C. Karapetis C. Zalcberg J. Tu D. Au H. et al. (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040–2048.
33. Kabbinavar F. Schulz J. McCleod M. Patel T. Hamm J. Hecht J. et al. (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II Trial. J Clin Oncol 23: 3697–3705.
34. Kang W. (2014) Trial of XELIRI / FOLFIRI + simvastatin followed by simvastatin maintenance in metastatic colorectal cancer. http://clinicaltrials.gov/ct2/show/NCT01238094 (accessed 16 October 2014).
35. Koeberle D. Betticher D. von Moos R. Dietrich D. Brauchli P. Baertschi D. et al. (2013) Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: A randomized phase III noninferiority trial (SAKK 41/06). ASCO 2013. J Clin Oncol 31(Suppl.): abstract 3503.
36. Koopman M. Simkens Lieke H. Ten Tije A. Creemers G. Loosveld O. de Jongh F. et al. (2013) Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): the phase III CAIRO 3 study of the Dutch Colorectal Cancer Group (DCCG). ASCO 2013. J Clin Oncol 31(Suppl.): abstract 3502.
37. Lenz H. Niedzwiecki D. Innocenti F. Blanke C. Mahony M. O'Neil B. et al. (2014) CALGB / SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin(FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (Bv) or cetuximab (Cet) for patients (Pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon Or rectum (mCRC). ESMO 2014, abstract A5010.
38. Lièvre A. Bachet J. Le Corre D. Boige V. Landi B. Emile J. et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992–3995.
39. Loupakis F. Cremolini C. Masi G. Lonardi S. Zagonel V. Salvatore L. et al. (2014) Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014 371: 1609–1618.
40. Loven D. (2014) Maintenance metronomic chemotherapy for metastatic colorectal carcinoma. http://clinicaltrials.gov/ct2/show/NCT01668680 (accessed 16 October 2014).
41. Maughan T. Adams R. Smith C. Meade A. Seymour M. Wilson R. et al. (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN Trial. Lancet 377: 2103–2114.
42. Peeters M. Price T. Cervantes A. Sobrero A. Ducreux M. Hotko Y. et al. (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28: 4706–4713.
43. Perez-Staub N. Chibaudel B. Figer A. Cervantes A. Lledo G. Larsen A. et al. (2008) Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer? A GERCOR study. ASCO 2008. J Clin Oncol 26(Suppl.): abstract 4037.
44. Pugh C. (2014) FOCUS4: Molecular selection of therapy in colorectal cancer: a molecularly stratified randomised controlled trial programme. http://www.focus4trial.org/aboutfocus4/ (accessed 16 October 2014).
45. Saltz L. Clarke S. Diaz-Rubio E. Scheithauer W. Figer A. Wong R. et al. (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III Study. J Clin Oncol 26: 2013–2019.
46. Scheithauer W. (2014) Efficacy and safety of XELIRI + Avastin followed by XELOX + Avastin or reverse sequence in metastatic colorectal cancer (PASSION). http://clinicaltrials.gov/ct2/show/NCT02119026 (accessed 16 October 2014).
47. Schmoll H. Arnold D. de Gramont A. Ducreux M. Grothey A. O'Dwyer P. et al. (2014) MODUL–a multicentre randomised clinical trial of biomarker-driven therapy for the 1st-line maintenance treatment of metastatic colorectal cancer (mCRC): a signal-seeking approach. ESMO GI 2014, abstract 612.
48. Sobrero A. Maurel J. Fehrenbacher L. Scheitauer W. Abubakr Y. Lutz M. et al. (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26: 2311–2319.
49. Sobrero A. Peeters M. Price T. Hotko Y. Cervantes-Ruiperez A. Ducreux M. et al. (2012) Final results from study 181: randomized phase III study of FOLFIRI with or without panitumumab (Pmab) for the treatment of second-line metastatic colorectal cancer (mCRC). ASCO GI 2012. J Clin Oncol 30(Suppl. 4): abstract 387.
50. Tabernero J. Aranda E. Gomez A. Massuti B. Sastre J. Abad A. et al. (2010) Phase III study of first-line XELOX plus bevacizumab (Bev) for 6 Cycles followed by XELOX plus bev or single agent bev as maintenance therapy in patients with metastatic colorectal cancer: the MACRO trial (Spanish Cooperative Group for the Treatment of Digestive Tumors). ASCO 2010. J Clin Oncol 28(Suppl. 15): abstract 3501.
51. Tabernero J. Cohn A.L. Obermannova R. Bodoky G. Garcia-Carbonero R. Ciuleanu T.E. et al. (2015) RAISE: a randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp). J Clin Oncol 33(Suppl. 3): abstract 512.
52. Tebbutt N. Wilson K. Gebski V. Cummins M. Zannino D. van Hazel G. et al. (2010) Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized phase III MAX Study. J Clin Oncol 28: 3191–3198.
53. Tol J. Koopman M. Cats A. Rodenburg C. Creemers G. Schrama J. et al. (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360: 563–572.
54. Tournigand C. Andre T. Achille E. Lledo G. Flesh M. Mery-Mignard D. et al. (2004) FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229–237.
55. Tournigand C. Cervantes A. Figer A. Lledo G. Flesch M. Buyse M. et al. (2006) OPTIMOX1: A randomized study of FOLFOX 4 or FOLFOX 7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer–a GERCOR Study. J Clin Oncol 24: 394–400.
56. Trarbach T. (2014) Maintenance therapy with 5-FU/FA plus panitumumab vs. 5-FU/FA alone after prior induction and re-induction after progress for 1st-line treatment of metastatic colorectal cancer (PanaMa). http://clinicaltrials.gov/show/NCT01991873 (accessed 16 October 2014).
57. Tveit K. Guren T. Glimelius B. Pfeiffer P. Sorbye H. Pyrhonen S. et al. (2012) Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (NORDIC FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII Study. J Clin Oncol 30: 1755–1762.
58. van Cutsem E. Kohne C. Hitre E. Zaluski J. Chang Chien C. Makhson A. et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408–1417.
59. van Cutsem E. Kohne C. Lang I. Folprecht G. Nowacki M. Cascinu S. et al. (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011–2019.
60. van Cutsem E. Ohtsu A. Falcone A. Yoshino T. Garcia-Carbonero R. Mizunuma N. et al. (2014) Phase III RECOURSE trial of TAS-102 vs. placebo, with best supportive care (BSC), in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies. ESMO 2014, abstract LBA13.
61. van Cutsem E. Peeters M. Siena S. Humblet Y. Hendlisz A. Neyns B. et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658–1664.
62. van Cutsem E. Tabernero J. Lakomy R. Prenen H. Prausova J. Macarulla T. et al. (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30: 3499–3506.
63. Wasan H. Meade A. Adams R. Wilson R. Pugh C. Fisher D. et al. (2014) Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncol 15: 631–639.
64. Yoshino T. Mayer R. Falcone A. Ohtsu A. Garcia-Carbonero R. Mizunuma N. et al. (2014) Results of a multicenter, randomized, double-blind, phase III study of TAS-102 vs placebo, with best supportive care in patients with metastatic colorectal cancer refractory to standard therapies (RECOURSE). Ann Oncol 25: 114.
65. Yoshino T. Mizunuma N. Yamazaki K. Nishina T. Komatsu Y. Baba H. et al. (2012) TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13: 993–1001.